Print

Amsterdam Molecular Therapeutics (AMT) (RHP.DE) Holding N.V. (in liquidation) Announces Publication of its Accounts for 2011 and Notice of Annual General Meeting  
7/16/2012 10:04:24 AM

AMSTERDAM, July 13, 2012 /PRNewswire/ --

Amsterdam Molecular Therapeutics (AMT) Holding NV (in liquidation) (Euronext: AMT) published its Annual Report and Accounts for the year ended December 31, 2011 and announced that it will host its Annual General Meeting at its headquarters (Meibergdreef 61, 1105 BA Amsterdam Zuidoost, the Netherlands) at 14.00 hrs on September 12, 2012. Shareholders of the dissolved company are invited to attend.

For further details, agenda and voting information, visit: http://www.amtbiopharma.com/investors/shareholder-information

About Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidation)

On March 30, 2012, an extraordinary general meeting of shareholders approved a major corporate restructuring and financing transaction involving the disposal of AMT's entire business and operations to uniQure B.V. and the subsequent dissolution, liquidation and delisting of AMT. On April 5, the disposal completed and AMT's dissolution as resolved by the extraordinary general meeting of shareholders became effective, with Mr. Jörn Aldag and Mr. Piers Morgan being appointed as the liquidators charged with the liquidation of the company's dissolved property. On April 26, 2012, the liquidators made an advance distribution - consisting of depositary receipts for ordinary class B in uniQure B.V. - to AMT's shareholders. There will not be any further (final) distributions made to AMT shareholders.

AMT and the AMT shares will continue to exist until the liquidation is finalised, which is expected to occur before the end of 2012. AMT and its shares ceasing to exist upon the ending of the liquidation shall effectively also result in the delisting of AMT, to the extent the delisting cannot be achieved at an earlier date in consultation with Euronext Amsterdam and subject to such conditions as Euronext Amsterdam may propose.

Further information on AMT, can be found on AMT's website http://www.amtbiopharma.com.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on current expectations only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT (in liquidation). Actual results could differ materially from current expectations due to a number of factors and uncertainties. AMT (in liquidation) expressly disclaims any intent or obligation to update any forward-looking statements herein except as required by law.

PRN NLD

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V


//-->